- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed sees return of price squeeze in U.S.
Price pressure has returned to the U.S. contrast agent market after a brief period of relative stability, Norwegian contrast developer Nycomed reported late last month. Nycomed attributed the resurgence to heavier competition in the contrast market, as
Price pressure has returned to the U.S. contrast agent market after a brief period of relative stability, Norwegian contrast developer Nycomed reported late last month. Nycomed attributed the resurgence to heavier competition in the contrast market, as well as increased managed-care buying power and the consolidation of group purchasing organizations.
Nycomed's announcement echoes comments made by Mallinckrodt executives last month on the status of the U.S. market for contrast media (SCAN 10/1/97). Mallinckrodt said that heightened price pressure in the U.S. market would cause the company to report lower than expected earnings for the first quarter of fiscal 1998.
Nycomed's news on contrast pricing came as part of an update on the status of the company's proposed merger with Amersham International of the U.K. The merger proposal will be voted on by shareholders of both companies at meetings to be held Oct. 14 and 16. The expected closing date of the deal is Oct. 21.
In other Nycomed news, the company announced in September that it has been awarded a three-year contract to supply x-ray and MRI contrast products to University HealthSystem Consortium Services. Nycomed has also submitted a bid in connection with the renegotiation of a supply agreement it holds with another GPO that is set to expire at the end of this year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
